FDA
-
-
-
-
-
-
-
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
-
-
-
-
-
-
-
Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
-
-
-
-
-
-
-
Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
-
-
-
-
-
-
-
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
-
-
-
-
-
-
-
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
-
-
-
-
-
-
-
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”
-
-
-
-
-
-
-
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19
-
328,603 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

